NEXGEL Preannounces Expected Record Third Quarter 2024 Revenue of $2.85 Million, an Increase of Approximately 133% Year-Over-Year and 98% Sequentially
October 10 2024 - 8:00AM
NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a
leading provider of medical and over-the-counter (OTC) products
including ultra-gentle, high-water-content hydrogels for healthcare
and consumer applications, today announced preliminary, unaudited
expected record revenue for the third quarter 2024 of approximately
$2.85 million, an increase of approximately 133% year-over-year and
approximately 98% quarter-over-quarter, respectively, as well as an
increase of approximately 30% over the Company’s previously issued
July third quarter revenue guidance of $2.20 million.
“We are pleased to announce yet another record
revenue quarter, surpassing our internal forecasts in both branded
consumer products and contract manufacturing,” said Adam Levy,
NEXGEL’s CEO. “Our branded consumer product sales have seen
significant growth year-over-year and quarter-over-quarter in all
three brands led by our beauty brand Silly George. Additionally,
our contract manufacturing segment has returned to more normalized
revenue levels following our recent expansion initiatives, which
included doubling our square footage and installing
state-of-the-art automated machinery and related clean room
facilities. We anticipate continued positive momentum will carry
into the fourth quarter during which our first order of SilverSeal
will also be delivered to Cintas.”
NEXGEL will report its financial results for the
third quarter 2024 on or before November 14, 2024 and will host a
conference call the same day.
About NEXGEL, Inc.NEXGEL is a
leading provider of healthcare, beauty, and over-the-counter (OTC)
products including ultra-gentle, high-water-content hydrogels.
Based in Langhorne, Pa., the Company has developed and manufactured
electron-beam, cross-linked hydrogels for over two decades. NEXGEL
brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and
Silly George®. Additionally, NEXGEL has strategic contract
manufacturing relationships with leading consumer healthcare
companies.
Preliminary Third Quarter 2024
ResultsThis press release sets forth certain preliminary
estimates of financial and operating results that we expect to
report for the third quarter ended September 30, 2024. We are
currently in the process of finalizing our financial results for
the September 30, 2024 third quarter, and the preliminary estimated
financial information presented above reflects various assumptions
and estimates based upon preliminary information available to us as
of the date of this press release. This information should not be
viewed as a substitute for full unaudited financial statements
prepared in accordance with accounting principles generally
accepted in the United States for the third quarter ended September
30, 2024. Our independent registered public accounting firm has not
reviewed this preliminary estimated financial information. As a
result, it remains in all cases subject to change pending
finalization. Items or events may be identified or occur after
issuance of these preliminary results due to the completion of
operational and financial closing procedures. In addition, final
adjustments and other developments may arise that would require us
to make material adjustments to this preliminary financial
information. Therefore, our actual results may differ materially
from the current expectations expressed in this release.
Forward-Looking StatementThis
press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”) (which Sections were adopted as part of the
Private Securities Litigation Reform Act of 1995). Statements
preceded by, followed by or that otherwise include the words
“believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,”
“project,” “prospects,” “outlook,” and similar words or
expressions, or future or conditional verbs, such as “will,”
“should,” “would,” “may,” and “could,” are generally
forward-looking in nature and not historical facts. These
forward-looking statements, including but not limited to our
anticipation of continued positive financial momentum in the fourth
quarter of 2024, involve known and unknown risks, uncertainties and
other factors which may cause the Company's actual results,
performance, or achievements to be materially different from any
anticipated results, performance, or achievements for many reasons.
The Company disclaims any intention to, and undertakes no
obligation to, revise any forward-looking statements, whether as a
result of new information, a future event, or otherwise. For
additional risks and uncertainties that could impact the Company's
forward-looking statements, please see the Company's Annual Report
on Form 10-K for the year ended December 31, 2023, including but
not limited to the discussion under “Risk Factors” therein, which
the Company filed with the SEC and which may be viewed at
http://www.sec.gov/.
Investor Contacts:Valter Pinto,
Managing DirectorKCSA Strategic
Communications212.896.1254NEXGEL@KCSA.Com
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From Oct 2024 to Nov 2024
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From Nov 2023 to Nov 2024